KI EIS Growth Fund (HMRC Approved)

An HMRC approved EIS fund that invests in EIS qualifying growth-stage biotech companies covering novel drug discovery and AI/ML technologies.

Download Brochure

Request Info-Pack

*Capital at risk. Potential tax reliefs subject to individual circumstances. For sophisticated / high net worth investors only.

featured in

highlights

                                    HMRC-approved Knowledge Intensive EIS (KI EIS) Growth Fund, offering up to 30% income tax relief, carry-back, CGT deferral and potential IHT benefits (subject to individual circumstances)                                        
Invest in growth-stage UK biotech and human health companies, already progressing through clinical development or generating revenues, with clearer paths to exit                                        
Concentrated portfolio of 7–10 companies sourced from the o2h Ventures ecosystem, providing access to proprietary deal flow and high-conviction opportunities                                        

                                    Sunil Shah, CEO - o2h Ventures

fund overview

HRMC Approved	YES
Fund Status	Open, Closing on 5th April 2026
Target AUM	£10m
Expected Exit	5-7 years
Founders Investment	Minimum 10% of every investment

Download Brochure

EIS tax relief is very attractive for UK tax payers

You invest £50k

EIS gives you £15k tax relief from HMRC

EIS gives you £25k tax relief from HMRC

IF COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £15k income tax relief

- £10k performance incentive

= £55k net profit

IF VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £15k income tax relief

- £0 performance incentive

= £15k net profit

IF COMPANY FAILS

Investment now worth £0

£50k loss

+ £15k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £19,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

*Tax relief depends on an individual’s circumstances and may change in the future.

why o2h ventures?

+History in grassroots science: We have a track record of nurturing and investing in emerging life science and tech companies – the o2h ventures team are leaders in the biotech community and have been involved as investors, holding various board/industry positions awe well as being engaged in grassroot scientific activity for over 20 years.

+Evaluation: Since its inception, the o2h group has developed a rigorous process to evaluate its deal flow, particularly regards seed investments. Opportunities come from a wide range of sources, as a result of the o2h group’s extensive network of contacts.

+Access to scientific talents: The team have developed access to some of the most interesting scientific ideas and talent in the UK, achieving a clearly differentiated position through its live working relationships, fostered over many years, working as a discovery services company. This potentially fives o2h ventures earlier access than competitor to some of the most promising companies.

+Business model: The business model identified by o2h ventures gives it an edge both in terms of access to opportunities as well as an understanding of the support they require post investment in terms of incubation. By combining access and incubation we are providing a unique opportunity, reducing investment risk by being deeply involved and the team believe that this will increase Fund’s prospects of making successful exits.

fund registered with